Improving anxiety-induced insomnia with lavender oil29 Aug 2019
New data shows pharmaceutical-quality lavender oil significantly improves anxiety-induced insomnia when taken as a daily capsule.
Pharmaceutical-quality lavender oil has a significant anxiolytic (anxiety relieving) effect and improves insomnia when taken orally as a daily capsule, new data shows.
Disturbed sleep is a prevalent symptom in anxiety disorders and a key diagnosis criterion for subthreshold and generalised anxiety disorders (GAD). It is estimated that more than two thirds of patients with GAD suffer from insomnia, with even higher rates amongst the elderly, causing a detrimental effect on patients’ daily living skills and quality of life. In 80% of patients with diagnosed anxiety disorders, symptoms of insomnia appear simultaneously with anxiety symptoms(5) highlighting the importance of targeting insomnia in the treatment of anxiety.
Pharmacological anxiety treatments such as benzodiazepines carry a sedating effect. Although some patients may see a short-term improvement in sleep, common side effects of benzodiazepine use include daytime drowsiness and rebound insomnia – further intensifying sleep disturbances. Benzodiazepines can also cause a physical dependence and withdrawal reaction when taken for longer than the recommended 4 weeks, a common withdrawal symptom is insomnia making it hard for patients to break the anxiety-insomnia cycle.
A mediation analysis by researchers from the Universities of Zurich and Basel published this month in the Journal of Psychiatric Research, found that 98.4% of patients saw an improvement in anxiety-related sleep disturbances when taking a daily capsule of pharmaceutical quality lavender oil vs placebo. The results indicate that pharmaceutical quality lavender oil exerts a secondary sleep improving effect almost exclusively through its anxiety-relieving action rather than by sedation(.
Pharmaceutical quality lavender oil capsules are shown to decrease excessive neurotransmitter activity, reducing overstimulation and hyperactivity of the nervous response - improving symptoms of mild anxiety. More than 15 clinical trials show that a daily lavender oil capsule can be AS EFFECTIVE as commonly used anti-anxiety medication, including the benzodiazepine lorazepam prescribed in GAD without the risk of sedation, dependency or withdrawal.
Professor of Psychiatry, Professor Hans-Peter Volz comments: ‘’This is a positive development for anxiety. Research demonstrates that the lavender oil capsules reduce both physical and psychological symptoms of anxiety (including sleep disturbances), without issues such as sedation, addiction or withdrawal. Lavender oil capsules provide a promising alternative treatment option to prescription drugs for subthreshold anxiety sufferers.”
The anxiety-relieving effects of uniquely prepared, pharmaceutical quality lavender oil are available only in Kalms Lavender One-A-Day Capsules.
Nicky Lidbetter, CEO of Anxiety UK states: ‘’Anxiety is one of the most prevalent mental health conditions in the UK - one in five people report feeling anxious a lot or all of the time; and more than 45 million working days have been lost due to anxiety (combined with depression and stress) in the past three years. We welcome a range of treatment and support options, including the Kalms Lavender One-a-Day capsule and other non-prescription options such as talking therapies.”
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development
10 Sep 2019
Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.Read more
BioCity backs world's first Rx to OTC switch incubator
5 Sep 2019
Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.Read more
Dutch company receives €20 million for skin cancer diagnostic test
3 Sep 2019
The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.Read more
AbbVie axes Rovalpituzumab Tesirine R&D program
2 Sep 2019
Independent Data Monitoring Committee recommended terminating the study due to lack of survival benefit.Read more
Grant from Innovate UK to fund gel stabilisation technologies development
28 Aug 2019
Atelerix Consortium awarded £267,000 Innovate UK Grant for collaboration with the Cell and Gene Therapy Catapult and Rexgenero on cell therapy stabilisation technologies.Read more
Exciting new vaccine targets killer disease TB
28 Aug 2019
Australian researchers produce early-stage vaccine which is inhaled into the lungs.Read more
Rapid adoption of Carterra’s LSA instrument drives European expansion
20 Aug 2019
Company's antibody screening platform minimizes the risk of missing a blockbuster.Read more
IDT launches oPools Oligo Pools
19 Aug 2019
The longest, highest fidelity, and ready-to-use custom oligo pools on the market.Read more
FDA Approves rfxcel for Verification Router Service (VRS) Pilot
15 Aug 2019
rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.Read more
rfxcel Awarded ISO 9001:2015 Certification
14 Aug 2019
rfxcel, the leader in track and trace solutions for global supply chains announced that it is now ISO 9001:2015 certified for Quality Management Systems.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation